Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Guggenheim Healthcare Talks Idea Forum and Oncology Day Transcript

Feb 13, 2020 / 06:00PM GMT
Release Date Price: R$20.75 (-1.11%)
Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

All right. Thanks, everybody. I'm Seamus Fernandez, the large pharma analyst here at Guggenheim Securities. This is our second annual Oncology Day, and I'm really pleased to be joined by Eli Lilly. We have a number of members of the team here and in the audience. Up on stage here with us on the far left are -- is Dr. Maura Dickler. Dr. Dickler is Vice President of the Late-Phase Oncology Development Opportunities. We also have Eric Dozier, who's the Vice President of Oncology, North America. And beside him, I think many of you know Jake Van Naarden, who is the Chief Operating Officer of Loxo Oncology and joined Lilly, I think, a little over a year ago with the acquisition of Loxo Oncology. So with that, thank you all for joining us.

Questions & Answers

Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

There's a lot going on at Lilly Oncology. I guess for starters,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot